Literature DB >> 21685545

Antiviral effects of interferon-β are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3.

J Daniel Burke1, Nahum Sonenberg, Leonidas C Platanias, Eleanor N Fish.   

Abstract

BACKGROUND: Viral myocarditis is most frequently associated with infection by Coxsackievirus B3 (CVB3). Interferon (IFN)-β therapy has been studied and could reduce virally induced tissue damage and improve heart function.
METHODS: In the present study we have investigated the role of translational suppression in the context of an IFN-α/β-mediated antiviral immune response to CVB3 infection. Specifically, we examined the effects of IFN-α/β treatment of CVB3-infected mouse embryonic fibroblast cells and splenocytes lacking eukaryotic initiation factor 4E binding protein-1 (4E-BP1), a suppressor of 5'-capped mRNA translation. Extending these in vitro studies, we examined the effects of CVB3 infection and IFN-β treatment in 4E-BP1(-/-) mice.
RESULTS: Our data show that 4E-BP1(-/-) cells are more -sensitive to the antiviral effects of IFN-α4 and IFN-β treatment than 4E-BP1(+/+) cells when infected with CVB3. Similarly, 4E-BP1(-/-) mice are more sensitive to treatment with IFN-β, exhibiting lower viral titres in heart tissue than 4E-BP1(+/+) mice during the course of infection. Additionally, we demonstrate that treatment with IFN-β reduces inflammatory infiltrates into the hearts of infected mice.
CONCLUSIONS: These data identify 4E-BP1 as a novel drug target to augment responsiveness to IFN-β therapy in CVB3-induced myocarditis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685545      PMCID: PMC3142995          DOI: 10.3851/IMP1752

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  37 in total

1.  Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling.

Authors:  Surinder Kaur; Lakhvir Lal; Antonella Sassano; Beata Majchrzak-Kita; Maya Srikanth; Darren P Baker; Emmanuel Petroulakis; Nissim Hay; Nahum Sonenberg; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2006-11-17       Impact factor: 5.157

2.  Inhibition of protein trafficking by coxsackievirus b3: multiple viral proteins target a single organelle.

Authors:  Christopher T Cornell; William B Kiosses; Stephanie Harkins; J Lindsay Whitton
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Viral persistence in the myocardium is associated with progressive cardiac dysfunction.

Authors:  Uwe Kühl; Matthias Pauschinger; Bettina Seeberg; Dirk Lassner; Michel Noutsias; Wolfgang Poller; Heinz-Peter Schultheiss
Journal:  Circulation       Date:  2005-09-19       Impact factor: 29.690

4.  Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection.

Authors:  M A Opavsky; J Penninger; K Aitken; W H Wen; F Dawood; T Mak; P Liu
Journal:  Circ Res       Date:  1999-09-17       Impact factor: 17.367

5.  Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response.

Authors:  Michael J Stewart; Kathleen Smoak; Mary Ann Blum; Barbara Sherry
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction.

Authors:  Uwe Kühl; Matthias Pauschinger; Michel Noutsias; Bettina Seeberg; Thomas Bock; Dirk Lassner; Wolfgang Poller; Reinhard Kandolf; Heinz-Peter Schultheiss
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

7.  2A proteinases of coxsackie- and rhinovirus cleave peptides derived from eIF-4 gamma via a common recognition motif.

Authors:  W Sommergruber; H Ahorn; H Klump; J Seipelt; A Zoephel; F Fessl; E Krystek; D Blaas; E Kuechler; H D Liebig
Journal:  Virology       Date:  1994-02       Impact factor: 3.616

8.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Protective role for interferon-beta in coxsackievirus B3 infection.

Authors:  Raj Deonarain; Dante Cerullo; Koichi Fuse; Peter P Liu; Eleanor N Fish
Journal:  Circulation       Date:  2004-07-12       Impact factor: 29.690

10.  Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro.

Authors:  M Joachims; P C Van Breugel; R E Lloyd
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  6 in total

1.  Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3.

Authors:  J D Burke; L C Platanias; E N Fish
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 2.  Update on coxsackievirus B3 myocarditis.

Authors:  DeLisa Fairweather; Katelyn A Stafford; Yoon K Sung
Journal:  Curr Opin Rheumatol       Date:  2012-07       Impact factor: 5.006

Review 3.  Regulation of interferon-dependent mRNA translation of target genes.

Authors:  Barbara Kroczynska; Swarna Mehrotra; Ahmet Dirim Arslan; Surinder Kaur; Leonidas C Platanias
Journal:  J Interferon Cytokine Res       Date:  2014-02-21       Impact factor: 2.607

Review 4.  Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.

Authors:  Eleanor N Fish; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2014-09-12       Impact factor: 5.852

5.  Acute myocarditis mimicking ST-elevation myocardial infarction: A case report and review of the literature.

Authors:  Tao Zhang; Wei Miao; Shixuan Wang; Min Wei; Guohai Su; Zhenhua Li
Journal:  Exp Ther Med       Date:  2015-06-12       Impact factor: 2.447

6.  Expression Levels of MicroRNA-146b and Anti-Cardiac Troponin I in Serum of Children with Viral Myocarditis and Their Clinical Significance.

Authors:  Min Yan; Jing Wang; Suyun Wang; Yang Zhang; Ling Liu; Hua Zhao
Journal:  Iran J Public Health       Date:  2021-03       Impact factor: 1.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.